Beam Therapeutics presents updated Phase 1/2 BEAM-302 data at ERS 2026
Beam Therapeutics presented updated clinical data from its Phase 1/2 BEAM-302 trial for alpha-1 antitrypsin deficiency at the European Respiratory Society Congress 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.